APA (7th ed.) Citation

LG, P., TE, C., A, P., JS, L., JF, G., GA, O., . . . H, B. (2023). Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 18(1), 79. https://doi.org/10.1016/j.jtho.2022.08.014

Chicago Style (17th ed.) Citation

LG, Paz-Ares, et al. "Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 18, no. 1 (2023): 79. https://doi.org/10.1016/j.jtho.2022.08.014.

MLA (9th ed.) Citation

LG, Paz-Ares, et al. "Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 18, no. 1, 2023, p. 79, https://doi.org/10.1016/j.jtho.2022.08.014.